RECRUITING

Improving Attention in Individuals With Long COVID-19

Talk to us

Conditions

Long CovidCOVID-19Brain Fog

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is to find out if the Attention Processing Training program is a potential treatment for brain fog symptoms, reported by people with Long-Covid. Also investigating the feasibility of completing this program virtually.

Official Title

Intensive Attention Training to Treat Brain Fog in Individuals With Long-Covid

Quick Facts

Study Start:2024-03-22
Study Completion:2027-03-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06503874

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Aged 18-65 years. Live in the Chicagoland area
  2. * A history of confirmed SARS-CoV-2 infection.
  3. * Subjective reports of cognitive symptoms that interfere with everyday activities, starting on or shortly after SARS-CoV-2 infection.
  4. * Continuation or development of Long-Covid brain fog 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation.
  5. * Objective attentional deficits as measured by the Conners CPT-312, and/or the Digit Span subtest (WAIS- III13).
  6. * Able to use a keyboard.
  7. * Able to understand and communicate in English.
  8. * Able to consent independently.
  1. * Being hospitalized due to COVID-19 diagnosis for more than 3 days.
  2. * Pre-morbid neurological conditions that could potentially affect cognition, such as Parkinson's Disease, Alzheimer's Dementia, acquired brain injury.
  3. * Severe depression.
  4. * Currently enrolled in cognitive training or physical exercise training.
  5. * Receiving chemotherapy or radiation within last 6 months.
  6. * Active substance abuse.

Contacts and Locations

Study Contact

Kathryn Magee, MHS
CONTACT
(312)238-6451
LongCovid@sralab.org

Principal Investigator

Shira Cohen-Zimerman, PhD
PRINCIPAL_INVESTIGATOR
Shirley Ryan AbilityLab
Elliot Roth, MD
PRINCIPAL_INVESTIGATOR
Shirley Ryan AbilityLab

Study Locations (Sites)

Shirley Ryan AbilityLab
Chicago, Illinois, 60611
United States

Collaborators and Investigators

Sponsor: Shirley Ryan AbilityLab

  • Shira Cohen-Zimerman, PhD, PRINCIPAL_INVESTIGATOR, Shirley Ryan AbilityLab
  • Elliot Roth, MD, PRINCIPAL_INVESTIGATOR, Shirley Ryan AbilityLab

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-22
Study Completion Date2027-03-01

Study Record Updates

Study Start Date2024-03-22
Study Completion Date2027-03-01

Terms related to this study

Keywords Provided by Researchers

  • COVID-19
  • Brain Fog

Additional Relevant MeSH Terms

  • Long Covid